DDInter41 DDInter298
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) palliates {v} (Disease) brain cancer
brain cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) MT2A
MT2A {u} (Gene) is bound by {v} (Compound) Carboplatin
Alemtuzumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cladribine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Alemtuzumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cladribine {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) palliates brain cancer (Disease) and brain cancer (Disease) is treated by Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds SLC31A1 (Gene) and Bortezomib (Compound) upregulates SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Carboplatin (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) downregulates MT2A (Gene) and MT2A (Gene) is bound by Carboplatin (Compound)
Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)
Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Carboplatin (Compound)